Introduction {#S1}
============

Turbinate surgery is very common and has been reported as the eighth most common procedure performed by otolaryngologists [@R01] [@R02]. Bilateral inferior turbinate enlargement occurs in patients suffering from allergic seasonal or perennial rhinitis or vasomotor non-allergic rhinitis with more frequent hyperplasia of the head of the turbinate. Furthermore, chronic inflammatory condition may lead to hyperplasia of the mucosa and sub-mucosa, generally observed on the end of the turbinate, or morphologically presenting as polypoid formation of new tissue [@R03]^-^[@R05].

At least 13 surgical techniques have been used over the past 130 years [@R01]. All authors agree that in modern functional nasal surgery there is no place for total or subtotal turbinectomy due to the risk of haemorrhage, postoperative pain and longterm complications, and especially atrophic rhinitis [@R06]. All reduction techniques are successful, but vary significantly in terms of long-term efficacy and risk of complications. Nevertheless, no ideal standard technique has been developed to date, and in particular there is a lack of prospective and comparable long-term studies, which makes it difficult to recommend evidence-based surgical techniques [@R07]^-^[@R10].

The aim of our study was to assess the long-term results of radiofrequency volumetric tissue reduction (RFVTR) of the inferior turbinates in patients with nasal obstruction caused by turbinate hypertrophy.

Materials and methods {#S2}
=====================

This single institution longitudinal prospective study was performed at the Department of Head and Neck Surgery Otorhinolaryngology of Catholic University of the Sacred Heart in Rome. The protocol was approved by our institutional board. All subjects gave written informed consent. From January 2004 to December 2010, 337 patients (205 males, 132 females), aged between 18-71 years, underwent RFVTR for treatment of simple bilateral hypertrophy of the turbinates that was not responsive to three-months of conservative therapy (intranasal sprays, antihistamines, systemic decongestants, mast cell stabilisers and allergic desensitisation) [@R10] [@R11].

A total of 305 (133 female and 172 male) of 337 patients were included for statistical analyses and 32 were excluded because they were lost to follow-up. Of these, 37.37% (114/305) of patients were affected by allergic rhinitis and 62.63% (191/305) by non-allergic rhinitis. Subjects were followed for a mean period of 39.70 ± 19.41 months (range 24-60).

Pre-operative clinical evaluation included complete history and physical head and neck examination with nasal endoscopy, allergy testing through serum total IgE, allergometric skin testing for common inhalant allergens and determination of the levels of specific IgE in serum. In all patients we excluded chronic rhinosinusitis (according to the criteria of EPOS guidelines [@R08] for chronic rhinosinusitis), previous head and neck cancer, prior radiation therapy, rhinoplasty, active nasal infection, severe septal deformity, septal perforation, facial anomalies, connective tissue disorder and autoimmune disease, or nasal valve region deformity).

Patients were asked to complete a NOSE Scale questionnaire [@R09] pre-operatively, and then post-operatively at 1 month ([Table I](#T1){ref-type="table"}) and yearly for a maximum of 5 years. In the first month subjects were followed every week for 4 weeks to complete early evaluation of symptoms such as pain, rhinorrhoea, itching, sneezing, crusting and congestion scored by visual analogue scale (VAS) (range 0-10). The patient was asked to indicate on a VAS the answer to the question: \"How troublesome are your symptoms?\". Patients were told that 0 indicated \'nasal symptoms not at all bothersome\' and that 10 indicated \'nasal symptoms extremely bothersome\'. At 4 weeks after surgery patients were asked to formulate a final global evaluation of the procedure using a VAS scale (range 0-10). Successively, patients were followed-up for recurrence at yearly intervals for a maximum of 5 years. At every follow-up patients were asked about the need to restart medical treatment and the NOSE scale questionnaire was repeated. We obtained for every patient a total NOSE scale score from 0 to 20; then scaled to a total NOSE score from 0 to 100 multiplying the scores of the five items by 5. Recurrence was assumed if the post-operative total NOSE score increased by at least 75% during followup and the patient restarted medical treatments.

###### 

NOSE scale questionnaire.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
      NOSE scale                                                             Over the past 1 month how much of a problem were the following conditions for you?\               
                                                                             Please mark the most correct response                                                             
  --- ---------------------------------------------------------------------- ------------------------------------------------------------------------------------- --- --- --- ---
  1   Nose obstruction and stuffiness                                        0                                                                                     1   2   3   4

  2   Nose blockage or obstruction                                           0                                                                                     1   2   3   4

  3   Trouble breathing through my nose or mouth breathing                   0                                                                                     1   2   3   4

  4   Trouble sleeping                                                       0                                                                                     1   2   3   4

  5   Unable to get enough air through my nose during exercise or exertion   0                                                                                     1   2   3   4
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

All procedures were performed in outpatient facilities with local anaesthesia using cotton strips with a 1:1 mixture of lidocaine and xylometazoline hydrochloride and conscious or deep sedation with midazolam or propofol. No premedication was given. Pain during the procedure was scored as none, mild, moderate and severe.

The surgery was performed using a radiofrequency system Celon Lab Precision (Olympus). Radiofrequency creates ionic agitation in tissue, inducing hypertermic sub-mucosal necrosis. The target temperature can be controlled from 60°C to 75°C to prevent surrounding tissue damage. It allows safe and gentle sub-mucosal volume reduction of hyperplastic nasal turbinate, developing predictably sized lesions in 4-10 sec. The resultant wound contraction and fibrosis of the sub-mucosa causes volume reduction of the inferior turbinate without damage to the overlying mucosa that adheres to the turbinate periosteum. This conservative procedure also damages sub-mucosal nerve fibres and the receptor nerve leading to denervation and hyporeactivity of turbinate mucosa. We never performed turbinate outfracture in combination with RFVTR [@R10]^-^[@R12].

Technically, the probe is introduced into the turbinate head under direct vision making 3-4 tunnels and maintaining a sufficient distance from the mucosa and bone. The process of ablation is accompanied by an acoustic tone that rises in pitch as the resistance of the tissue increases. No packing or antibiotic therapy was used after the operation.

For statistical analysis, we used Stata IC 12 software for MAC. The results are shown as mean and standard deviation(SD), median and interquartile range(IQR) or frequency relative percentages, as appropriate. With regards to outcome variables, comparisons between time 0 (PRE-intervention) and time 1 (4 weeks POST-intervention) were performed using a paired t-test. Kaplan-Meier analysis was used to estimate recurrence over time; the comparison between two relapse curves was made by the log-rank test. The results were considered statistically significant for p values \< 0.05.

Results {#S3}
=======

During surgery we obtained a good rate of pain control that was considered absent in 225/305 patients (73.7%), mild in 40/305 (13.3%), moderate in 20/305 (6.5%) and severe in 20/305 (6.5%). A few patients (26/305; 8.5%) required prescription of analgesics after the procedure. The procedures were well tolerated as demonstrated by the early post-operative evaluation (1 week after surgery) using mean VAS values scores of symptoms such as nasal airway obstruction, crusting, sneezing, runny nose and itching ([Table II](#T2){ref-type="table"}).

###### 

Post-operative mean VAS scores (range 0-10) and standard deviation of symptoms at early evaluation 1 week after surgery.

  VAS scale                 Mean   SD
  ------------------------- ------ -----
  Nasal obstruction         0.9    2.0
  Rhinorrhoea               2.0    2.8
  Itching                   1.2    2.1
  Sneezing                  1.9    2.3
  Crusting                  2.6    2.8
  Intermittent Congestion   4.7    3.1
  Persistent Congestion     4.6    3.0

Results of anesthesiological questionnaires are shown in [Table III](#T3){ref-type="table"}. In the first months after surgery, the mean global evaluation score was of 7.3 ± 2.1, indicating good satisfaction of patients. No immediate complications such as major bleeding related to the treatment were observed after radiofrequency. Only 4 of 305 patients (1.3%) had postoperatively bleeding and nasal packing was needed. The most common complaints were transient side effects, including minor nasal discharge and post-procedural obstruction for up to 5-7 days. Subjects\' estimation of symptoms by the NOSE scale was repeated at every follow-up evaluation. The mean baseline nose scale score and comparison to post-operative values at 1 month after the procedure are showed in [Figure 1](#F1){ref-type="fig"} and [Table IV](#T4){ref-type="table"}. We evaluated the temporal trend of the benefit obtained with surgery for the items of the NOSE scale that significantly improved as shown in [Figure 2](#F2){ref-type="fig"}. We observed a worsening trend of the benefit obtained even though some patients experienced no change of benefit for extended periods. We also evaluated the temporal trend of global satisfaction of patients measured by VAS score (range 0-10) as shown in [Figure 3](#F3){ref-type="fig"}.

###### 

Anaesthesiologic questionnaire and results.

  ---------------------------------------------------- ------------------------------ --------------------- -------------------- ------------------
  **Pain control during the procedure**                **No pain**\                   **Mild pain**\        **Moderate pain**\   **Severe pain**\
                                                       225/305 (73.7%)                40/305 (12.9%)        20/305 (6.5%)        20/305 (6.5%)

  **Anxiety during the procedure**                     **Yes** 76/305 pts (24.91%)\                                              
                                                       **No** 225/305 pts (73.7%)                                                

  **Recovery time**                                    **Minutes**\                   **Hours**\                                 
                                                       260/305 pts (85.24%)           50/305 pts (16.39%)                        

  **Other problems (nausea, sickness, shiver etc.)**   **Yes** 70/305 pts (22.9%)\                                               
                                                       **No** 120 pts (77.4%)                                                    
  ---------------------------------------------------- ------------------------------ --------------------- -------------------- ------------------

###### 

Comparisons between time 0 (PRE intervention) and time 1 (4 week POST intervention) mean and median nose scale scores.

  -------------------------------------------------------------------------------------------------------------------------------------------------------
           Nose congestion or\    Nose blockage or\       Trouble breathing\    Trouble sleeping\   Unable to get enough\                           
           stuffiness p \< 0.05   obstruction p \< 0.05   through my nose\      p \> 0.05           air through my nose\                            
                                                          or mouth breathing\                       during exercise or\                             
                                                          p \< 0.05                                 exertion\                                       
                                                                                                    p \> 0.05                                       
  -------- ---------------------- ----------------------- --------------------- ------------------- ----------------------- ----- ----- ----- ----- -----
  Mean     3.6                    1.7                     3.7                   1.8                 3.7                     1.6   1.5   1.3   1.1   0.7

  SD       1.2                    1.1                     1.2                   1.2                 1.2                     1.2   1.4   1.3   1.2   1.1

  Median   4                      2                       4                     2                   4                       2     1     1     1     0

  IQR      1                      2                       1                     2                   1                       1     3     2     2     1
  -------------------------------------------------------------------------------------------------------------------------------------------------------

![The figure shows differences respect to baseline of NOSE scale scores items comparing time 0 (PRE intervention) and time 1 values (4 week POST intervention). (1) Nose obstruction and stuffiness. (2) Nose blockage or obstruction. (3) Trouble breathing through my nose or mouth breathing. (4) Trouble sleeping. (5) Unable to get enough air through my nose during exercise or exertion.](0392-100X-36-199-g001){#F1}

![Temporal trend of the benefit obtained with surgery considering evolution during long-term follow-up of mean NOSE scores for items that significantly improved after surgery.](0392-100X-36-199-g002){#F2}

![Temporal trend of global patient satisfaction evaluated during longterm follow-up by the VAS score (range 0-10). The indicator represents the mean VAS scores about global satisfaction at each follow-up visit.](0392-100X-36-199-g003){#F3}

Estimation of recurrence was performed in all patients by Kaplan Meyer analysis as shown in [Figure 4](#F4){ref-type="fig"}. The cumulative probability to remain relapse-free was 0.848 at 36 months and 0.531 at 60 months after surgery as shown in [Table V](#T5){ref-type="table"}. In order to test if allergy could be a discriminating factor in the impact of intervention, the analysis of recurrence was stratified by the presence of allergy ([Fig. 5](#F5){ref-type="fig"}). The analysis showed that allergic patients seemed to be worse in the post-intervention period compared to nonallergic patients, and in particular at long-term follow-up. In fact, cumulative probability to remain relapse-free in allergic and non-allergic patients was respectively 0.839 vs 0.807 at 36 months, and 0.616 vs 0.357 at 60 months ([Table V](#T5){ref-type="table"}). The log rank test revealed that the difference between curves was statistically significant (p \< 0.05).

###### 

Cumulative probability to remain free of relapse obtained by Kaplan Meyer analyses in all patients and in allergic and non-allergic patients.

                          Months of follow-up                           
  ----------------------- --------------------- ------- ------- ------- -------
  All patients            0.993                 0.928   0.848   0.722   0.531
  Non-allergic patients   0.989                 0.930   0.839   0.729   0.616
  Allergic patients       0.934                 0.902   0.807   0.575   0.357

![Estimation of recurrence over time by Kaplan-Meier analysis in all 305 patients enrolled.](0392-100X-36-199-g004){#F4}

![Estimation of relapse over time by Kaplan-Meier analysis in allergic patients (n = 114) and non-allergic patients (n = 191). The difference between curves was significant by log rank test.](0392-100X-36-199-g005){#F5}

Discussion {#S4}
==========

Reduction of the inferior turbinates can be performed using different surgical techniques including total or partial inferior turbinectomy (PIT), lateral outfracture, microdebrider submucosal resection, laser-assisted turbinate reduction, argon plasma surgery, cryosurgery, treatment with infrared light, vidian neurectomy, chemical or electrical coagulation and radiofrequency volume turbinate reduction (RFVTR) [@R12]^-^[@R14]. The literature [@R12]^-^[@R15] provides considerable evidence for the efficacy of \"hot surgery\" in adults with symptomatic, inferior turbinate hypertrophy, with a significant increase in use of these techniques in the past decade. Important adverse effects of these techniques are likely the consequence of the heat generated by the power applied. Atrophic and metaplastic changes of mucosa, crusting and synechia may occur, and the incidence differs for the administered energy with various long-term results [@R16]^-^[@R21].

Several studies have shown [@R22]^-^[@R26] that RFVTR can be considered as a safe mini-invasive surgical procedure with only slight nasal mucosa damage, minor discomfort and a low risk of side effects. However, most published studies are observational and have a relatively short followup, while reports of long-term assessment of self reported benefits and patient satisfaction of treatment are insufficient. Porter et al. [@R27] in a small series showed that after two-years of follow-up there was no significant return of symptoms compared to evaluation at 6 months. Garzaro et al. [@R12] evaluated patients at 2 months and 2 years after the surgical procedure using the \"Sniffin\' Sticks\" test battery and the NOSE scale. Long-term evaluation showed that radiofrequency treatment for allergic or non-allergic inferior turbinate hypertrophy appeared to provide improvement in olfaction, decrease in nasal resistance and had subjective benefits that were maintained at 2 years after the procedure. Cukurova et al. [@R10] demonstrated that most patients (82%) showed long-term (60 months) subjective and objective improvement after only one procedure. Safiruddin et al. [@R28] analysed the self-reported long-term effects of RFVTR treatment using a questionnaire sent to 441 patients who underwent RFA. They included a total of 142 patients. Subjective data retrieved through patient interviews showed a trend of beneficial effect of RFVTR on nasal breathing during daytime, with 60.7% of patients reporting long-term improvement after treatment.

Our data showed overall good satisfaction of patients with the procedure together with a good rate of pain control during surgery and a low rate of complications (1.3% bleeding). Post-operatively we observed (4 weeks after surgery) a significant improvement in nasal stuffiness, nasal obstruction and mouth breathing ([Table IV](#T4){ref-type="table"}, [Fig. 1](#F1){ref-type="fig"}). We analysed the temporal trend of the benefit obtained with surgery and observed a worsening trend as shown in [Figure 2](#F2){ref-type="fig"}. We also observed a mild worsening trend of global satisfaction of patients as shown in [Figure 3](#F3){ref-type="fig"}. We followed patients over time for recurrence by the Kaplan Meyer method. At the early follow-up for at least 36 months the majority of patients maintained benefits achieved with surgery, and in this time period the cumulative probability to remain relapse free was up to 0.8 as shown in [Table V](#T5){ref-type="table"}. In the following years, we observed an increasing rate of recurrence with a decrease in cumulative relapse-free probability.

Taking into consideration the increasing prevalence of allergic rhinitis, its impact on individual quality of life and social costs, we investigated if allergy could be a discriminating factor in the impact of the intervention, and in particular on early exacerbations. Limited data are available in the literature on this topic because most published studies on RF turbinate surgery in patients with allergic rhinitis have a relatively short follow-up. Recently, some authors have suggested that urban residence and allergic rhinitis were significantly associated with lower long-term improvement after radiofrequency treatment [@R29]. Furthermore, Linet al. [@R11] demonstrated that even though the outcome of RF turbinate reduction for patients with allergic rhinitis responding poorly to medical therapy decreases over time, it was still significant at 5 years after surgery. Herein, it was possible to stratify the analysis of recurrences by the presence of allergy, observing a worse temporal trend in allergic patients compared to non-allergic ones with a statistically significant difference (p \< 0.05). Our data suggest that allergy affects results of surgery in terms of recurrence at long-term follow-up.

In conclusion, our data confirm that treatment of hyperplastic inferior nasal turbinates due to chronic allergic and nonallergic vasomotor rhinitis by minimally invasive nasal- RFA can be considered a safe procedure that alters nasal mucosa only slightly, while preserving physiologic function with minor discomfort and a low risk of side effects. In fact, the procedure is quick, easy, relatively painless and has the additional benefit of not requiring post-operative nasal packing, with satisfactory results. Furthermore, it appears to be a successful therapeutic option that offers very good results for at least 36 months. In the following 2 years, we observed a worse temporal trend in terms of recurrence rates, especially in allergic patients. Prediction of relapse after this procedure is a challenge for the future, and in particular to improve the success rate. In this regard, the severity and type of inflammation that causes turbinate hypertrophy is one of the factors that should be investigated. Several studies [@R30]^-^[@R35] have recently demonstrated that inflammation has a very important role in the pathogenesis of the swelling of nasal mucosa, not only in allergic rhinitis, but also in non-allergic rhinitis. Further studies should clarify whether the type and severity of inflammation correlate with the therapeutic success of this procedure.
